Cortexyme Announces Agreement to Acquire Novosteo

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat...

Click to view original post